GSK Expands Exdensur’s Reach in China: A New Option for Difficult-to-Treat Nasal Polyps

Global biopharma leader GSK plc has secured another regulatory win in China.

China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on therapy for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who remain uncontrolled despite standard treatments.

This follows closely on the heels of its recent approval in severe eosinophilic asthma—signaling a broader push into type 2 inflammatory diseases.

What This Approval Covers?

Exdensur is now approved in China for:

• Adults with CRSwNP
• Patients not adequately controlled by:
  • Systemic corticosteroids
  • Surgery

It is used alongside intranasal corticosteroids as an add-on therapy.

Why This Matters: A Large Unmet Need?

CRSwNP is more than just a nasal condition. Patients often experience:

• Persistent nasal blockage
• Loss of smell
• Facial pain and pressure
• Sleep disruption
• Recurrent infections

And here’s the key problem:

• ~50% of patients remain uncontrolled
• Up to 85% are driven by type 2 inflammation

This makes long-term disease control extremely challenging with existing therapies.

What Makes Exdensur Different?

1. Ultra-Long-Acting Biologic

Exdensur stands out as:

• The first ultra-long-acting biologic in this category
• Designed for twice-yearly dosing

That’s a major shift from frequent injection schedules seen with other biologics.

2. Targets the Root Cause

Depemokimab works by targeting interleukin-5 (IL-5):

• A key cytokine driving type 2 inflammation
• Central to diseases like asthma and CRSwNP

Result: Sustained suppression of underlying inflammation—not just symptom relief.

The Clinical Evidence: ANCHOR Trials

The approval is backed by ANCHOR-1 and ANCHOR-2 Phase III trials.

Key outcomes at 52 weeks:

• Reduction in nasal polyp size (NPS score)
• Improvement in nasal obstruction symptoms
• Strong statistical significance across endpoints

Additionally:

• Safety profile was comparable to placebo
• Well tolerated across patient groups

These trials included over 500 patients with severe, uncontrolled CRSwNP.

Building a Multi-Indication Blockbuster

This isn’t a one-indication drug. Exdensur is already approved for:

• Severe asthma (US, China, EU, Japan, UK)
• CRSwNP (multiple global markets)

And it’s being evaluated in Phase III trials for:

• Eosinophilic granulomatosis with polyangiitis (EGPA)
• Hyper eosinophilic syndrome (HES)
• COPD with type 2 inflammation

Translation: GSK is building a platform biologic across multiple inflammatory diseases.

Strategic Implications for GSK

1. Doubling Down on Respiratory & Immunology

GSK has long been a leader in respiratory medicine.

This approval strengthens its position in:

• Biologics-driven care
• Chronic inflammatory diseases
• High-value specialty therapeutics

2. Expanding in China

China is a critical growth market for biologics.

This move:

• Expands patient access
• Strengthens GSK’s regulatory footprint
• Positions the company in a high-demand segment

3. Redefining Treatment Convenience

According to Kaivan Khavandi: Exdensur could redefine care with just two doses a year.

That’s not incremental innovation, it’s a compliance game-changer.

The Bigger Trend

This approval reflects a broader shift in pharma:

From Symptom Control → Disease Modification

Instead of managing symptoms, companies are targeting:

• Underlying immune pathways
• Long-term disease progression

Final Takeaway

Exdensur isn’t just another biologic. It represents a new treatment paradigm:

• Fewer doses
• Deeper disease control
• Broader applicability across inflammatory conditions

For GSK, this is more than a product expansion. It’s a strategic step toward owning the future of type 2 inflammation therapies.